While the phase III trial success rate for drugs who have successfully completed phase II is overall above 50% it varies depending on the therapeutic field. Eg for oncology drugs it is only around 35% whereas for ophthalmic drugs it is almost 75%! With respect to the Carlyle group they report a success rate of 86% for the phase III trial companies they’ve invested in.
Ann: Opthea secures up to US$170m in non-dilutive financing, page-20
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |